Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Determination of mean recency period for estimation of HIV type 1 incidence with the BED-capture EIA in persons infected with diverse subtypes
AIDS Research and Human Retroviruses, Volume 27, No. 3, Year 2011
Notification
URL copied to clipboard!
Description
The IgG capture BED enzyme immunoassay (BED-CEIA) was developed to detect recent HIV-1 infection for the estimation of HIV-1 incidence from cross-sectional specimens. The mean time interval between seroconversion and reaching a specified assay cutoff value [referred to here as the mean recency period (ω)], an important parameter for incidence estimation, is determined for some HIV-1 subtypes, but testing in more cohorts and new statistical methods suggest the need for a revised estimation of ω in different subtypes. A total of 2927 longitudinal specimens from 756 persons with incident HIV infections who had been enrolled in 17 cohort studies was tested by the BED-CEIA. The ω was determined using two statistical approaches: (1) linear mixed effects regression (ω1) and (2) a nonparametric survival method (ω2). Recency periods varied among individuals and by population. At an OD-n cutoff of 0.8, ω1 was 176 days (95% CL 164-188 days) whereas ω2 was 162 days (95% CL 152-172 days) when using a comparable subset of specimens (13 cohorts). When method 2 was applied to all available data (17 cohorts), ω2 ranged from 127 days (Thai AE) to 236 days (subtypes AG, AD) with an overall ω2 of 197 days (95% CL 173-220). About 70% of individuals reached a threshold OD-n of 0.8 by 197 days (mean ω) and 95% of people reached 0.8 OD-n by 480 days. The determination of ω with more data and new methodology suggests that ω of the BED-CEIA varies between different subtypes and/or populations. These estimates for ω may affect incidence estimates in various studies. © 2011, Mary Ann Liebert, Inc.
Authors & Co-Authors
Parekh, Bharat S.
United States, Atlanta
Centers for Disease Control and Prevention
Hanson, Debra L.
United States, Atlanta
National Center for Hiv, Viral Hepatitis, Std, and tb Prevention
Hargrove, John W.
South Africa, Stellenbosch
Stellenbosch University
Branson, Bernard M.
United States, Atlanta
National Center for Hiv, Viral Hepatitis, Std, and tb Prevention
Green, Timothy A.
United States, Atlanta
National Center for Hiv, Viral Hepatitis, Std, and tb Prevention
Dobbs, Trudy L.
United States, Atlanta
Centers for Disease Control and Prevention
Constantine, Niel T.
United States, Baltimore
University of Maryland, Baltimore Umb
Overbaugh, Julie M.
United States, Seattle
Fred Hutchinson Cancer Research Center
McDougal, John Steven
United States, Atlanta
National Center for Hiv, Viral Hepatitis, Std, and tb Prevention
Statistics
Citations: 96
Authors: 9
Affiliations: 5
Identifiers
Doi:
10.1089/aid.2010.0159
ISSN:
08892229
Research Areas
Infectious Diseases
Study Design
Cross Sectional Study
Cohort Study